Core Scientific (CORZR) Liabilities and Shareholders Equity (2020 - 2026)

Core Scientific's Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $3.1 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 104.9% year-over-year to $3.1 billion; the TTM figure through Mar 2026 stood at $9.4 billion (up 111.51% YoY), while the FY2025 annual figure was $2.3 billion, up 59.06% from the prior year.
• Liabilities and Shareholders Equity came in at $3.1 billion for Q1 2026 at Core Scientific, up from $2.3 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $3.1 billion in Q1 2026 to a low of $664.2 million in Q2 2024.
• A 5-year average of $1.4 billion and a median of $1.4 billion in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity surged 677.6% in 2022 and slumped 71.89% in 2023, its largest moves.
• Core Scientific's Liabilities and Shareholders Equity stood at $807.7 million in 2022, then dropped by 11.83% to $712.2 million in 2023, then soared by 107.25% to $1.5 billion in 2024, then surged by 59.06% to $2.3 billion in 2025, then soared by 30.75% to $3.1 billion in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $3.1 billion, $2.3 billion, and $2.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison